Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in infants and toddlers with moderate-to-severe atopic dermatitis
2025-525027-27-00Phase 2Authorised
- Sponsor
- Galderma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Primary endpoints: Observed nemolizumab serum concentrations, Population pharmacokinetic predicted steady-state parameters and 1 more. Planned start Sep 2026; status: authorised.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-525027-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525027-27-00.